In both cases, hyperactive receptor tyrosine kinases, epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) potentiate common downstream Ras and phosphatidylinositol 3-kinase/Akt pathways to drive tumour growth and survival18, 19. The gene discussed is AKT1; the disease is neoplasm.